Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer.

Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute p...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Merigan, T C, Gallagher, J G, Pollard, R B, Arvin, A M
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1981
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181382/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6166245/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.1.193
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!